Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for anti-AChR positive generalized myasthenia gravis
ChiCTR2500109279Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept in myasthenia gravis (MG) (2 arms), sponsored by First Hospital of China Medical University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2500109279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109279.